@article{cde2c8061d0246aabe67a78ab2c62973,
title = "The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study",
abstract = "Background This study aims to compare the effectiveness of EEG frequency band activity including interhemispheric asymmetry and prefrontal theta cordance in predicting response to escitalopram therapy at 8-weeks post-treatment, in a multi-site initiative. Methods Resting state 64-channel EEG data were recorded from 44 patients with a diagnosis of major depressive disorder (MDD) as part of a larger, multisite discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND). Clinical response was measured at 8-weeks post-treatment as change from baseline Montgomery-Asberg Depression Rating Scale (MADRS) score of 50% or more. EEG measures were analyzed at (1) pre-treatment baseline (2) 2 weeks post-treatment and (3) as an {\textquoteleft}{\textquoteleft}early change” variable defined as change in EEG from baseline to 2 weeks post-treatment. Results At baseline, treatment responders showed elevated absolute alpha power in the left hemisphere while non-responders showed the opposite. Responders further exhibited a cortical asymmetry in the parietal region. Groups also differed in pre-treatment relative delta power with responders showing greater power in the right hemisphere over the left while non-responders showed the opposite. At 2 weeks post-treatment, responders exhibited greater absolute beta power in the left hemisphere relative to the right and the opposite was noted for non-responders. A reverse pattern was noted for absolute and relative delta power at 2 weeks post-treatment. Responders exhibited early reductions in relative alpha power and early increments in relative theta power. Non-responders showed a significant early increase in prefrontal theta cordance. Conclusions Hemispheric asymmetries in the alpha and delta bands at baseline and at 2 weeks post-treatment have moderately strong predictive utility in predicting response to antidepressant treatment.",
keywords = "Alpha asymmetry, Depression, EEG power, Escitalopram, Theta cordance",
author = "{the CAN-BIND Investigators Team} and Anusha Baskaran and Faranak Farzan and Roumen Milev and Brenner, {Colleen A.} and Sravya Alturi and {Pat McAndrews}, Mary and Pierre Blier and Ken Evans and Foster, {Jane A.} and Frey, {Benicio N.} and Peter Giacobbe and Lam, {Raymond W.} and Francesco Leri and MacQueen, {Glenda M.} and M{\"u}ller, {Daniel J.} and Parikh, {Sagar V.} and Susan Rotzinger and Soares, {Claudio N.} and Strother, {Steven C.} and Gustavo Turecki and Kennedy, {Sidney H.}",
note = "Funding Information: Financial support for this study was provided by the Ontario Brain Institute, with additional funding support from Canadian Institutes of Health Research (CIHR), Lundbeck, Bristol-Myers Squibb, Pfizer, and Servier. Funding and/or in kind support was also provided by the investigators{\textquoteright} universities and academic institutions. Funding Information: Trainee support for this study was provided through the Canadian Biomarker Integration Network in Depression (CAN-BIND). CAN-BIND is an Integrated Discovery Program carried out in partnership with, and financial support from, the Ontario Brain Institute, an independent non-profit corporation, funded partially by the Ontario government. The opinions, results and conclusions are those of the authors and no endorsement by the Ontario Brain Institute is intended or should be inferred. Additional funding is provided by the Canadian Institutes of Health Research (CIHR), Lundbeck, Bristol-Myers Squibb, Pfizer, and Servier. Funding and/or in kind support is also provided by the investigators{\textquoteright} universities and academic institutions. All study medications are independently purchased at wholesale market values. Funding Information: Trainee support for this study was provided through the Canadian Biomarker Integration Network in Depression (CAN-BIND). CAN-BIND is an Integrated Discovery Program carried out in partnership with, and financial support from, the Ontario Brain Institute, an independent non-profit corporation, funded partially by the Ontario government. The opinions, results and conclusions are those of the authors and no endorsement by the Ontario Brain Institute is intended or should be inferred. Additional funding is provided by the Canadian Institutes of Health Research (CIHR), Lundbeck, Bristol-Myers Squibb, Pfizer, and Servier. Funding and/or in kind support is also provided by the investigators{\textquoteright} universities and academic institutions. All study medications are independently purchased at wholesale market values. Publisher Copyright: {\textcopyright} 2017",
year = "2018",
month = feb,
doi = "10.1016/j.jad.2017.10.028",
language = "English (US)",
volume = "227",
pages = "542--549",
journal = "Journal of affective disorders",
issn = "0165-0327",
publisher = "Elsevier",
}